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Background. Intestinal tuberculosis (ITB) constitutes less than 5% of overall cases of extrapulmonary disease and mostly affects the
ileocecal region. The presentation and radiologic findings in enteric tuberculosis can mimic Crohn’s disease (CD). Case Presentation. We present a case report of an African woman who presented to a Kenyan hospital with lower gastrointestinal bleeding
while on anticoagulation for valvular atrial fibrillation, and was diagnosed with intestinal tuberculosis after colonoscopy, biopsy,
and positive staining for tuberculous bacilli. Conclusion. Intestinal tuberculosis causing gastrointestinal bleeding is rare but should
be suspected in patients living in TB endemic regions.

1. Introduction
Tuberculosis (TB), an infection caused by Mycobacterium
tuberculosis, is the tenth leading cause of death worldwide
and the most common caused by a single infectious agent in
the pre-COVID-19 pandemic era. The World Health Organization (WHO) Global Tuberculosis Report of 2020
estimated that there were 10 million cases of active tuberculosis worldwide and 1.2 million deaths in the preceding
year. 90% of the infections were in thirty high TB burden
countries including Kenya [1]. The country has an estimated
TB prevalence of 558 per 100000 adults [2].
The primary infection site in most cases is the lungs, but
virtually any other organ can be affected, which is referred to
as extrapulmonary TB (EPTB). Abdominal involvement can
be in solid organs, peritoneum, intestine, or lymph nodes.
Intestinal tuberculosis (ITB) constitutes less than 5% of
overall cases of EPTB cases, and although, it can involve the
entire gastrointestinal tract (GIT), the most common sites of
involvement are the ileocecal area, colon, and small bowel
[3]. In contrast, the upper gastrointestinal tract, namely, the
esophagus and stomach are rare sites of infection [4, 5].

Enteric TB can be a result of different modes of spread: direct
infection by ingestion of bacilli from infected food or
sputum, spread from an adjacent organ, and hematogenous
or lymphatic spread [6].
The clinical presentation and diagnostic findings of ITB
can mimic other infections, malignancies, and inflammatory
bowel disease (IBD) [7]. Although infectious causes predominate in the developing nations, the prevalence of IBD is
rising in these countries [8]. Crohn’s disease (CD), one of the
forms of IBD, shares many clinicopathologic features with
GIT TB, and each can lead to misdiagnosis of the other with
the risk of deleterious outcomes [9, 10]. This is compounded
by the low sensitivities of tests used to ascertain the diagnosis
of GIT TB [10, 11].
EPTB has been shown to have worse outcomes in
treatment, compared to lung disease [5]. A source of
concern in abdominal TB is the risk of complications including fistula formation, perforation, and intestinal obstruction [12]. It is essential that the diagnosis is made and
appropriate treatment is initiated. Here, we describe a case
of a young female who presented with gastrointestinal
bleeding while on warfarin therapy for atrial fibrillation
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and rheumatic heart disease, whose workup including
imaging, endoscopy, and histology established a diagnosis
of ITB in the setting of active pulmonary disease. CD was
considered a diﬀerential diagnosis during the investigation
of the patient.

2. Case
A thirty-ﬁve-year-old female presented with complaints of
per rectal bleeding mixed with stools. She had recurrent
episodes associated with crampy lower abdominal pain over
a period of ﬁve days. Upon further enquiry, she also reported
a history of productive cough for three months, night
sweats, and weight loss of ten kilograms over the same
period. Her medical history was signiﬁcant for rheumatic
heart disease and atrial ﬁbrillation. The patient had a surgical
history of mitral valvuloplasty two years prior to her current
presentation. Her regular medications included warfarin
5 mg daily, carvedilol 25 mg twice daily, and furosemide
40 mg daily. The examination revealed a sick-looking
middle-aged female who had pallor, bipedal edema, and no
palpable lymphadenopathy. The precordial examination was
positive for features of mitral stenosis and aortic regurgitation. Abdominal examination did not elicit any tenderness
or palpable mass. Investigations done included a complete
blood count with the following results: white cell count
9.24 × 109/L, hemoglobin 5.30 g/dL, and platelets 572 × 109/
L. The prothrombin time was prolonged, and the international normalized ratio (INR) was 2.78. Renal and hepatic
function tests were normal. Initial management involved
withholding of warfarin and transfusion of three units of
packed red cells. An urgent colonoscopy performed to
evaluate hematochezia revealed segmental inﬂammation of
the ascending colon with ulcerations and polyps covered
with yellowish exudate, a distended ileocecal junction, and
an aberrant vascular pattern with mucosal edema extending
to the hepatic ﬂexure (Figure 1). At endoscopy, the differential diagnoses were tuberculosis or CD. In view of her
respiratory complaints and accompanying systemic symptoms, a computed tomography (CT) of the chest and abdomen was performed, which demonstrated right lung
consolidation, focal subsegmental consolidations in the left
lung, and subcentimeter-sized lymph nodes in the small
bowel mesentery (Figure 2). Given her history of chronic
cough and chest imaging ﬁndings, a sputum test was
requested whose staining was acid-fast bacilli (AFB) positive. Biopsies of the samples obtained during colonoscopy
revealed lymphocytic inﬁltration, necrotizing granulomas,
and positivity for AFB (Figure 3). Serologic testing for
human immunodeﬁciency virus (HIV) was negative. A
diagnosis of pulmonary and extra pulmonary tuberculosis
with gastrointestinal involvement was established. The patient was initiated on the intensive phase of antituberculous
therapy consisting of rifampicin (600 mg/day), isoniazid
(300 mg/day), ethambutol (800 mg/day), and pyrazinamide
(1 g/day). Warfarin 5 mg daily was reinstituted prior to her
discharge after a ﬁve-day hospital admission. The culture in
Löwenstein-Jensen medium later isolated Mycobacterium
tuberculosis complex, which was susceptible to the ﬁrst-line
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drugs. She is followed up at the outpatient clinic with regular
INR checks to ensure a therapeutic INR range of 2.0-3.0. Her
warfarin dosage was increased from the initial 35 mg/week
to 52.5 mg/week by the fourth week after discharge.

3. Discussion
We present a case of ITB in a patient with concomitant
pulmonary disease whose main presenting symptom was
hematochezia while on warfarin therapy for atrial ﬁbrillation
and previous mitral valve surgery. The workup for an etiology of the gastrointestinal bleeding was pursued concurrently with that for her other complains identiﬁed on
systemic enquiry. Although the patient is from a high TB
burden country, a diﬀerential diagnosis of CD was considered during the initial investigations.
Extrapulmonary tuberculosis can be a manifestation of
coexisting lung disease. The rate of coexistence of pulmonary
and ITB has been reported to be in the range of 15–30%
[4, 13]. The patient in our case had conﬁrmation of active
lung disease in addition to enteric TB. The likely mode of
intestinal infection in such cases is ingestion of infected
sputum.
The most common presentation of GIT TB is abdominal
pain, which is reported by up to three quarters of patients
[10, 13, 14]. Other symptoms include weight loss, fever,
night sweats, and diarrhea. The patient in our case presented
with hematochezia, which is a rare presentation of GIT TB,
only seen in 7–20% of cases [10, 12, 13]. The cause of
bleeding is postulated to be due to endarteritis caused by the
bacilli [12]. A confounder in our case was the patient’s use of
warfarin. Mucosal inﬂammation due to infection is the likely
major contributor to bleeding in our case. In a study to
evaluate the etiology of major gastrointestinal bleeding in
patients on anticoagulants, colitis was identiﬁed as the
culprit lesion in 3% of patients on warfarin therapy [15].
Warfarin was resumed at discharge for our patient after a
ﬁve-day admission duration. Reinitiation of anticoagulation
after a clinically signiﬁcant lower gastrointestinal bleeding is
a challenging decision for clinicians because of the risk of
recurrence of bleeding and the beneﬁts of prevention of
thromboembolism. Discontinuation of warfarin has been
associated with an increased mortality in patients after
admission for LGIB. The risk factors associated with mortality were age and medical comorbidities, in particular
malignancies [16]. Our patient was young and had a low
Charlson comorbidity index, therefore, placing her at low
risk of adverse outcomes after the resumption of warfarin.
The optimal timing for restarting warfarin is unknown and
relies on clinical judgement of when the beneﬁts outweigh
the risks. In a review article, Kido and Scalese recommend
resumption of warfarin therapy within 7–15 days after a
major gastrointestinal bleed [17].
The constellations of symptoms of ITB are nonspeciﬁc,
leading to either a long duration prior to diagnosis or
misdiagnosis. In one report, the diagnosis of enteric TB was
not considered initially in more than 60% of patients who
had the eventual diagnosis [4]. The mimics include other
infections, malignancies, and inﬂammatory bowel disease.
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Figure 1: Colonoscopy: ulcerations and polyps in the ileocecal region and ascending colon.

Figure 2: CT chest axial image showing bilateral lung
consolidations.

CD was considered as a diﬀerential diagnosis during evaluation of our patient. Both ITB and CD have similar clinical,
radiological, endoscopic, and pathological features, therefore, making it a challenging clinical problem [10]. In a
report from China, in one of the high TB burden countries,
up to 17% of patients with ITB were initially misdiagnosed to
have CD [13]. Although TB is prevalent in the sub-Saharan
African region, an increase in CD is also being reported [8].
It is crucial to identify the correct diagnosis because the use
of immunosuppressive medications for CD can lead to ﬂare
up of TB with potential disastrous complications [18]. A
meta-analysis showed the following features correlating with
ITB more than CD: presentation with fever, night sweats,
and lung disease. Other features include patulous ileocecal
valve, cecal involvement, and presence of granulomas [19].
The patient in our case had all the above features favoring
ITB over CD even prior to microbiological conﬁrmation. In
particular, the chest imaging ﬁndings which prompted
sputum evaluation for TB was the key in our evaluation and

should be performed in patients with colitis, especially in
high TB endemic areas.
The colonoscopy ﬁnding of ileocecal involvement in our
case was in keeping with other studies as the most common
site in ITB [4, 6, 9, 20]. The reasons are postulated to be
increased contact time between the mycobacteria and mucosa
due to narrowing and stasis. Presence of lymphoid rich tissue
in the ileocecal region, to which bacilli have a predilection for
infecting, is also a possible contributory factor [21].
Biopsy of intestinal tissue for histology can be achieved
by endoscopy as in our case. Other methods include percutaneously with imaging guidance, by endoscopic ultrasound, and surgically, either open or laparoscopic [6]. The
demonstration of Mycobacterium in intestinal biopsy
specimens can be by acid-fast staining, nucleic acid ampliﬁcation, or culture. In addition, histologic ﬁndings of
caseating granuloma are considered a hallmark in TB diagnosis [6]. The biopsy from patient in our case was positive
for granulomas, AFB staining, and culture. PCR was not
performed on the biopsy specimen. Although these tests are
key in diagnosis, the sensitivity of any of the tests in ITB is
low, with ranges of 5.3–37.5% for AFB tissue staining,
23–46% for mycobacterial culture, and 36.4–67.9% for PCR
[19]. Because of the low sensitivities, a majority of patients in
the high TB prevalence countries are only diagnosed retrospectively after successful empiric treatment with antituberculous medications despite initial extensive diagnostic
investigations [9, 11, 13, 14].
The mainstay of treatment of ITB is medical therapy
consisting of combination antituberculous therapy administered during intensive phase and maintenance phase. In
drug susceptible TB, as in our case, the ﬁrst-line medications
during a two-month intensive phase are rifampicin, isoniazid, pyrazinamide, and ethambutol. The total duration of
treatment is at least six months, though some advocate for
extended durations of 9 or 12 months [4, 6]. The shorter
course of treatment has been found to be just as eﬀective as
an extended period, with the added beneﬁts of better
compliance and savings on cost [22]. The role of adjuvant
surgery is limited to complications such as intractable
bleeding, obstruction, and ﬁstulae [6].
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Figure 3: Colonic biopsies. (a) Lamina propria shows expansion by inﬂammatory cells. A lymphoid aggregate (red asterix), nonneoplastic
colonic glands (red dashed arrow), and granuloma are seen (yellow dashed line) (hematoxylin and eosin, original magniﬁcation x100).
(b) Goblet mucin component decreased as well as cryptitis. Edge of granuloma is seen here (original magniﬁcation x200). (c) Acid-fast bacilli
(black arrows) (Ziehl–Neelsen stain).

A potential challenge in the outpatient follow-up of this
case was the interaction between warfarin and rifampicin.
Rifampicin is an inducer of cytochrome P450 hepatic enzymes which metabolize warfarin. Thus, there is a risk of
inadequate anticoagulation in patients on both agents. It is
recommended that INR be checked every two weeks in such
cases and appropriate dose adjustments of warfarin be done
to achieve a therapeutic INR.
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4. Conclusion

The authors would like to thank members of their department for their valuable input in reviewing the case.

ITB is a manifestation of abdominal spread of disease and
should be suspected in patients presenting with gastrointestinal bleeding and constitutive symptoms in endemic areas.
Although the clinical, radiologic, and endoscopic features are
similar to CD, screening for pulmonary disease and microbiologic staining for specimens obtained during surgery, endoscopy, or radiologically can diagnose TB. The key treatment
is a standard course of ﬁrst-line antituberculous drugs.
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